BRAF and colorectal carcinoma: These are important findings since KRAS and PIK3CA mutations occur in approximately 60% and 20% of CRC, respectively.26 In LS411N (BRAF V600E mutated) cells, the combination Palbociclib with Gedatolisib demonstrated mild synergy whilst the combination Palbociclib with PD0325901 failed to show any synergistic effects (CI = 0.64 versus 14.7).